StockpollyBeta
Get App
Popularity #2,135
TNXP · NASDAQ · Biotechnology

Tonix Pharmaceuticals (TNXP)

Commercializes TONMYA for fibromyalgia alongside branded acute migraine treatments.

$10.07
vs last close−0.52 (−4.89%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue4422332235714
Cost of revenue242321131221
Gross profit201−1111−124513
302722171724182735524655
Research & development21171310987119171819
910980161000352836
Selling & marketing0000012000000
General & administrative90980310000036
Other expenses00008001626000
Operating income−28−27−21−18−16−22−16−28−33−48−42−43
0—6−6010−101112
Interest income0−20000011110
Other non-operating income00−660−1010−1−1−1−2
Income before tax−28−27−15−79−14−22−17−28−32−47−40−41
Net income from continuing operations−28−27−15−79−14−22−17−28−32−47−40−41
Net income−28−27−15−79−14−22−17−28−32−47−40−41
EPS, basic−$38.63−$6,178.26−$576.00−$1,928.00−$0.23−$9.77−$2.84−$3.86−$3.59−$4.28−$2.93−$2.44
EPS, diluted−$38.63−$6,178.26−$576.00−$1,928.00−$0.23−$9.77−$2.84−$3.86−$3.59−$4.28−$2.93−$2.44
Weighted average shares, basic72346267991417
Weighted average shares, diluted72346267991417
EBITDA−27−26−14−78−14−22−16−28−32−46−40−40
Depreciation & amortization111110000011
EBIT−28−27−15−79−14−22−17−28−32−47−40−41